FDA Class II Recall: Glenmark's Azelaic Acid Gel Faces CGMP Deviations, Impacting U.S. Supply
Glenmark Pharmaceuticals Inc., USA has initiated a Class II recall for 14,004 cartons of Azelaic Acid Gel, 15%, due to CGMP deviations at its Indian manufacturing facility. This voluntary action, impacting U.S. nationwide distribution, necessitates immediate supply chain risk assessment for procurement and regulatory teams, highlighting the critical need for robust supplier qualification and diversified sourcing strategies.
FDA Class II Recall: Glenmark's Azelaic Acid Gel Impacted by CGMP Deviations
Glenmark Pharmaceuticals Inc., USA, based in Mahwah, NJ, has initiated a Class II recall for 14,004 cartons of its Azelaic Acid Gel, 15%, distributed nationwide across the U.S. This critical action, designated recall number D-0621-2024, commenced on July 22, 2024, and was classified by the FDA on July 29, 2024. The primary reason cited for this voluntary, firm-initiated recall is deviations from Current Good Manufacturing Practices (CGMP). For procurement directors and regulatory affairs heads, a Class II recall signifies that the use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. This classification demands immediate attention to inventory management and patient safety protocols. The affected product, identified by NDC 68462-626-52 and Lot# 19241453 with an expiration of March 2026, is a human prescription drug primarily used topically for its effects on decreasing protein synthesis and sebaceous gland activity, commonly associated with dermatological conditions. Business development executives must recognize that such CGMP issues, even if firm-initiated, can erode market confidence and necessitate a swift, transparent response to maintain commercial relationships and ensure uninterrupted patient access.
Global Manufacturing Footprint: Implications of Glenmark India's Role in U.S. Supply
The recalled Azelaic Acid Gel, 15%, while marketed by Glenmark Pharmaceuticals Inc., USA from Mahwah, NJ, is manufactured by Glenmark Pharmaceuticals Limited at its facility in Colvale-Bardez, Goa, India. This dual-entity structure highlights the inherent complexities and risks associated with global pharmaceutical supply chains. For supply chain VPs, this event underscores the critical importance of rigorous oversight and auditing of overseas manufacturing partners, even those within the same corporate family. CGMP deviations at an international facility can directly compromise product quality and regulatory compliance for U.S. market distribution. The product, approved under ANDA204637, is a generic formulation, meaning its availability relies on a robust and compliant manufacturing base. Any disruption originating from the Indian manufacturing site can have immediate and significant repercussions for U.S. market supply. This incident serves as a stark reminder that geographical distance does not diminish regulatory accountability, and procurement strategies must account for the compliance status of every link in the global manufacturing chain. Ensuring consistent quality from international sites is paramount to avoiding costly recalls and maintaining market presence for essential generic drugs.
U.S. Market Supply Chain Exposure: Azelaic Acid Availability and Procurement Challenges
The recall of 14,004 cartons of Azelaic Acid Gel, 15%, distributed U.S. nationwide, presents a tangible supply chain exposure for distributors, pharmacies, and healthcare providers. Procurement directors must immediately assess their current inventory levels of NDC 68462-626-52 and identify any stock from the affected Lot# 19241453. While Azelaic Acid is a generic topical medication, a recall of this magnitude can lead to localized shortages, particularly in regions heavily reliant on Glenmark's supply. The impact extends beyond the immediate product; it signals potential vulnerabilities within Glenmark's broader manufacturing quality systems. Business development executives should anticipate inquiries from downstream partners regarding supply continuity and quality assurance. This event highlights the necessity for robust contingency planning and the proactive identification of secondary or tertiary suppliers, even for established generic molecules. The cost of managing a recall, including reverse logistics and potential lost sales, far outweighs the investment in a diversified and resilient supply chain. Furthermore, the ongoing status of the recall indicates that the full extent of the market impact and remediation efforts is still unfolding, requiring continuous monitoring by all stakeholders.